scholarly journals CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma

Oncotarget ◽  
2019 ◽  
Vol 10 (66) ◽  
pp. 7058-7070 ◽  
Author(s):  
Adi Zheng ◽  
Nadja Chevalier ◽  
Margot Calderoni ◽  
Gilles Dubuis ◽  
Olivier Dormond ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Genome Wide ◽  
Sensitivity Gene

scholarly journals A genome-wide CRISPR cell growth screen identifies NCAPG as a new therapeutic target for hepatocellular carcinoma

2017 ◽  
Vol 28 ◽  
pp. vii14 ◽  
Author(s):  
Y. Wang ◽  
B. Gao ◽  
P.Y. Tan ◽  
Y.A. Handoko ◽  
K. Sekar ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Growth ◽  
Therapeutic Target ◽  
Genome Wide ◽  
A Genome

scholarly journals Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma

Hepatology ◽  
2011 ◽  
Vol 54 (4) ◽  
pp. 1227-1236 ◽  
Author(s):  
Deshui Jia ◽  
Lin Wei ◽  
Weijie Guo ◽  
Ruopeng Zha ◽  
Meiyan Bao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Copy Number ◽  
Cancer Genes ◽  
Genome Wide

scholarly journals Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma

2020 ◽  
pp. HEP36
Author(s):  
Pierre Nahon ◽  
Manon Allaire ◽  
Jean-Charles Nault ◽  
Valérie Paradis
Keyword(s):  
Hepatocellular Carcinoma ◽  
Fatty Liver Disease ◽  
Association Studies ◽  
Cost Effective ◽  
Genome Wide Association Studies ◽  
Alcoholic Fatty Liver ◽  
Genome Wide ◽  
High Prevalence ◽  
Prevalence Of Obesity ◽  
Alcoholic Fatty Liver Disease

Hepatocellular carcinoma (HCC) developed in non-alcoholic fatty liver disease (NAFLD) individuals presents substantial clinical and biological characteristics, which remain to be elucidated. Its occurrence in noncirrhotic patients raises issues regarding surveillance strategies, which cannot be considered as cost-effective given the high prevalence of obesity and metabolic syndrome, and furthermore delineates specific oncogenic process that could be targeted in the setting of primary or secondary prevention. In this context, the identification of a genetic heterogeneity modulating HCC risk as well as specific biological pathways have been made possible through genome-wide association studies, development of animal models and in-depth analyses of human samples at the pathological and genomic levels. These advances must be confirmed and pursued to pave the way for personalized management of NAFLD-related HCC.

Genome-Wide Analysis of Gene Expression in Hepatocellular Carcinoma

2004 ◽  
pp. 74-83
Author(s):  
Taro Yamashita ◽  
Shuichi Kaneko ◽  
Masao Honda ◽  
Kenichi Kobayashi
Keyword(s):  
Gene Expression ◽  
Hepatocellular Carcinoma ◽  
Genome Wide Analysis ◽  
Genome Wide
Sign in / Sign up

Export Citation Format

Share Document